We are live on ! Find out more
RI

RTW Investments Portfolio holdings

AUM $10B
1-Year Est. Return 135.35%
This Fund
S&P 500
This Quarter Est. Return
+8.43%
1 Year Est. Return
+135.35%
3 Year Est. Return
+383.62%
5 Year Est. Return
+523.94%
10 Year Est. Return
+15,981.64%
AUM
$5.25B
AUM Growth
+$451M
Cap. Flow
+$312M
Cap. Flow %
5.94%
Top 10 Hldgs %
53.61%
Holding
70
New
10
Increased
19
Reduced
1
Closed
8

Top Buys

Rank Stock Value
1
BRKR icon
Bruker
BRKR
+$135M
2
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$106M
3
MDGL icon
Madrigal Pharmaceuticals
MDGL
+$60M
4
RARE icon
Ultragenyx Pharmaceutical
RARE
+$52.6M
5
ISRG icon
Intuitive Surgical
ISRG
+$51.4M

Top Sells

Rank Stock Value
1
RXDX
Prometheus Biosciences, Inc. Common Stock
RXDX
+$351M
2
VTYX
Ventyx Biosciences
VTYX
+$46.5M
3
APYX icon
Apyx Medical
APYX
+$8.21M
4
ALLK
Allakos
ALLK
+$5.9M
5
CSTL icon
Castle Biosciences
CSTL
+$5.87M

Sector Composition

Rank Sector Weight
1 Healthcare 99.97%
2 Financials 0.03%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MDGL icon
26
Madrigal Pharmaceuticals
MDGL
$11.8B
$51.2M 0.97%
+221,562
New +$60M
STOK icon
27
Stoke Therapeutics
STOK
$2.06B
$46.7M 0.89%
4,390,558
– –
TARS icon
28
Tarsus Pharmaceuticals
TARS
$2.85B
$46M 0.88%
2,548,125
– –
AXNX
29
DELISTED
Axonics, Inc. Common Stock
AXNX
$44.7M 0.85%
884,974
– –
OBIO icon
30
Orchestra BioMed
OBIO
$249M
$39.3M 0.75%
5,620,640
+502,133
+10% +$7.62M
SCPH
31
DELISTED
scPharmaceuticals
SCPH
$33.6M 0.64%
3,297,843
– –
CUTR
32
DELISTED
Cutera, Inc.
CUTR
$27.9M 0.53%
1,846,596
– –
MRUS
33
DELISTED
Merus
MRUS
$27.7M 0.53%
+1,050,893
New +$23M
GHRS icon
34
GH Research
GHRS
$2.1B
$25.7M 0.49%
2,168,957
– –
MLTX icon
35
MoonLake Immunotherapeutics
MLTX
$1.53B
$25.5M 0.49%
500,000
– –
INSM icon
36
Insmed
INSM
$28.7B
$21.1M 0.4%
+1,000,000
New +$19M
SLRN
37
DELISTED
ACELYRIN
SLRN
$20.4M 0.39%
+978,310
New +$20M
FULC icon
38
Fulcrum Therapeutics
FULC
$288M
$20M 0.38%
6,064,123
+552,284
+10% +$1.62M
MRVI icon
39
Maravai LifeSciences
MRVI
$922M
$19.1M 0.36%
+1,532,685
New +$20.7M
PMVP icon
40
PMV Pharmaceuticals
PMVP
$62.9M
$19M 0.36%
3,029,551
+30,453
+1% +$160K
GH icon
41
Guardant Health
GH
$21.1B
$17.9M 0.34%
500,887
+70,000
+16% +$2.01M
OM icon
42
Outset Medical
OM
$96.4M
$17.7M 0.34%
53,911
– –
VKTX icon
43
Viking Therapeutics
VKTX
$3.88B
$16.2M 0.31%
1,000,000
– –
MLYS icon
44
Mineralys Therapeutics
MLYS
$2.38B
$15.7M 0.3%
922,100
– –
ROIV icon
45
Roivant Sciences
ROIV
$25.4B
$15.7M 0.3%
1,552,717
– –
OLK
46
DELISTED
Olink Holding AB (publ) American Depositary Shares
OLK
$12.3M 0.23%
654,612
– –
IMUX icon
47
Immunic
IMUX
$198M
$10.8M 0.21%
429,446
– –
ACET icon
48
Adicet Bio
ACET
$74.1M
$10.3M 0.2%
265,092
– –
DSGN icon
49
Design Therapeutics
DSGN
$862M
$9.85M 0.19%
+1,563,031
New +$9.56M
IMTX icon
50
Immatics
IMTX
$1.29B
$9.75M 0.19%
845,000
– –
1
2
3

Similar funds

HRCM
Hood River Capital Management Palm Beach Gardens, Florida $9.98B AUM 145.42% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
GI
GAMCO Investors Greenwich, Connecticut $10.2B AUM 30.27% 1-Year Est. Return
IIM
INTECH Investment Management West Palm Beach, Florida $10.2B AUM 28.14% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
VPIM
Vanguard Personalized Indexing Management Oakland, California $10.2B AUM 34.45% 1-Year Est. Return
OIA
OneDigital Investment Advisors Overland Park, Kansas $10.2B AUM 16.58% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return

RTW Investments's Q2 2023 Portfolio in Review

As of Q2 2023, RTW Investments held 70 positions worth $5.25B, up 9.4% from $4.8B the previous quarter. Its ten largest holdings account for 54% of the portfolio.

RTW Investments deployed $312M of net new capital in Q2 2023, opening 10 new positions and adding to 19 existing holdings. Its largest new stake was Horizon Therapeutics Public Limited Company Ordinary Shares: 1,000,000 shares worth $103M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier, followed by Financials.

On the sell side, the largest reduction was Apyx Medical, an estimated $8.21M trimmed.

  • RTW Investments's largest Q2 2023 buy was Horizon Therapeutics Public Limited Company Ordinary Shares: 1,000,000 shares worth $103M.
  • RTW Investments added most to Bruker in Q2 2023, an estimated $135M increase.
  • RTW Investments's biggest Q2 2023 reduction was Apyx Medical, cutting an estimated $8.21M.
  • RTW Investments fully exited Prometheus Biosciences, Inc. Common Stock in Q2 2023, selling an estimated $351M.
  • RTW Investments's ten largest holdings make up 54% of its $5.25B portfolio in Q2 2023.
  • RTW Investments opened 10 new positions and closed 8 in Q2 2023.
  • RTW Investments's portfolio value rose 9.4% quarter-over-quarter to $5.25B.

Based on RTW Investments's 13F filing for Q2 2023, filed 14 Aug 2023.